Share

FDA approves drug for binge-eating disorder

accreditation
Binge-eater from Shutterstock
Binge-eater from Shutterstock


Vyvanse (lisdexamfetamine dimesylate) has been approved by the U.S. Food and Drug Administration to treat adults with recurring bouts of compulsive overeating known as binge-eating disorder.

Embarrassment and social isolation

It's the first drug sanctioned in the United States to treat the disorder, the agency said in a news release. Vyvanse was first approved in 2007 to treat attention deficit hyperactivity disorder (ADHD) for those aged six and older.

People with binge-eating disorder eat when they are not hungry, often to the point of being uncomfortably full, the FDA said. This may lead to embarrassment and social isolation.

Vyvanse's safety and effectiveness in treating binge-eating disorder were evaluated in clinical studies involving 724 people. A central nervous system stimulant, Vyvanse could cause serious complications including stroke and heart attack. It also could cause sudden death among users with heart problems, the FDA said.

Less serious side effects could include dry mouth, insomnia, increased heart rate, constipation, anxiety and feeling jittery.

The drug is marketed by Shire U.S., based in Wayne, Pensyllvania.

More information

The FDA has more about this approval.

Read:
Investigating binge eating disorder
How to treat binge eating disorder
Binge-eating kids may also do drugs

Image: Binge-eater from Shutterstock

We live in a world where facts and fiction get blurred
Who we choose to trust can have a profound impact on our lives. Join thousands of devoted South Africans who look to News24 to bring them news they can trust every day. As we celebrate 25 years, become a News24 subscriber as we strive to keep you informed, inspired and empowered.
Join News24 today
heading
description
username
Show Comments ()
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE